FDA Updates NDSRI Implementation Timelines – What You Need to Know

On June 23, 2025, FDA quietly revised its “CDER Nitrosamine Impurity Acceptable Intake Limits” webpage—updating the implementation timelines tied to its August 2023 RAIL Guidance for Nitrosamine Drug Substance-Related Impurities (NDSRIs). Here’s a breakdown of the new deadlines, flexibilities, and next steps.

1. Original Timeline Recap

• August 4, 2023: FDA issued the RAIL Guidance, setting AI limits and a target August 1, 2025 deadline for confirmatory testing and submission of required CMC changes for at-risk products. • September 4, 2024: FDA’s Nitrosamine Guidance (Rev 2) reinforced these timelines under a three-step control strategy.

2. June 23, 2025 Update Highlights

• Confirmatory Testing Deadline Remains – At-risk products must still complete confirmatory testing by August 1, 2025 using sensitive, validated methods. – Risk assessment and initial testing should be well underway now.
• New Flexibility: Progress Update Option – If you cannot submit full CMC supplements by August 1, FDA now lets you file a progress update instead of a full submission. – This flexibility acknowledges that “timeframes for full implementation… may vary depending upon the specific strategy” and that not all sponsors can meet the original deadline.

3. What to Include in Your Progress Update

Submit by August 1, 2025—via next Annual Report (section 1.13.14, titled “NDSRI Update”) or as a one-time AR revision. Your update should cover:

1. Whether NDSRIs form under targeted forced degradation
2. Detected NDSRIs (names/identifiers)
3. Analytical test method and validation status
4. Batch(es) analyzed and dates relative to manufacture
5. Quantitative confirmatory results (ng/day or ppm)
6. Root-cause analysis (if known)
7. Mitigation measures taken (if any)
8. Estimated completion timeline for full mitigation

Can’t provide any element? Submit an evidence-based justification instead.

4. What’s Next: Stay Tuned

FDA said it will:

• Issue additional communications on targeted timelines for required CMC changes
• Update the duration of interim AI limits (Table 3) in a future website revision

⚙️ Action Items for Manufacturers

• Confirm your at-risk API list (per RAIL Guidance).
• Fast-track analytical validation and forced-degradation studies.
• If full supplements aren’t ready, draft your NDSRI Update now.
• Coordinate cross-functionally: Analytical, CMC, Regulatory Affairs, and QA.
• Keep an eye on FDA’s next announcements—and plan to adjust your timelines accordingly.

Stay ahead of the curve—monitor FDA’s NDSRI page and prepare your progress report by August 1. Need help crafting your update or assessing risk? Drop us a line!